In this cross-sectional study, 8.5% of patients using proton pump inhibitors (PPIs) were rectal carriers of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E), compared with 2.9% of non-PPI users. In multivariable analysis, PPI use was independently associated with ESBL-E rectal carriage at hospital admission (adjusted odds ratio, 3.89; 95% confidence interval, 1.65 -9.19).
Rectal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in the general community has become endemic globally [1] . Several reservoirs for ESBL-E in the community setting have been described, including contaminated food. Whether oral exposure to ESBL-E results in ESBL-E rectal carriage will depend on several factors, such as the bacterial load of the exposure, functionality of the gastric barrier, and antibiotic use.
The use of medication that neutralizes or reduces the production of gastric acid has been shown to increase the risk of gastrointestinal infections [2] . Whether the use of such medication is associated with an increase in ESBL-E rectal carriage is less clear, and studies have reported conflicting results [3, 4] . The objective of this cross-sectional study was, therefore, to assess the association between proton pump inhibitor (PPI) use and ESBL-E rectal carriage at hospital admission.
METHODS
This cross-sectional study was performed in the Amphia Hospital, an 850-bed teaching hospital. Yearly, voluntary prevalence surveys for ESBL-E rectal carriage are performed as part of the routine infection control program. The current analysis is based on the prevalence surveys performed in November 2014 and November 2015, and includes all patients aged >18 years who were hospitalized for at most 2 days or received day care at the day of the survey. Patients who were hospitalized for >2 days were excluded to prevent the influence of hospital stay on ESBL-E rectal carriage.
ESBL-E rectal carriage was defined as the presence of genotypically confirmed ESBL-E in the rectal swab, and was detected by selective culturing of rectal swabs with subsequent phenotypic and genotypic confirmation of ESBL production for all Enterobacteriaceae grown, as described previously (Supplementary Data) [5] .
Infection control practitioners retrieved demographic and clinical patient data from the electronic medical patient records. These included gender, date of birth, date of admission, date of culture, hospital admission within the 6 months prior to current admission, medical speciality by which the patient was admitted, antibiotic use on the day of the survey, and preadmission use of PPIs and H 2 -receptor antagonists. Data on preadmission medication were collected from home-medication lists, which were verified on the day of admission by an assistant pharmacist. Infection control practitioners and assistant pharmacists were blinded to the culture results.
Data were analyzed using SPSS software (IBM SPSS Statistics 22.0, Armonk, New York). Univariable and multivariable logistic regression analyses were performed to examine whether PPI use was independently associated with ESBL-E rectal carriage. Based on the available literature on ESBL-E carriage and PPI use, age, antibiotic use on the day of culture, and hospital admission within the 6 months prior to the current hospital admission were included as potential confounding variables in the logistic regression analysis. The χ 2 test was used to test for differences in the distribution of ESBL genes between PPI users and non-PPI users. According to the Dutch regulations for research with human subjects, ethical approval was not required, as conduct of the ESBL-E prevalence surveys is part of the local hospital infection control program.
RESULTS
Valid rectal cultures were obtained from 570 of 702 (81.2%) hospitalized or day care patients. Of these 570 patients, 259 (45.4%; 95% confidence interval [CI], 41.4%-49.5%) used PPIs on admission. Antacids (n = 5) and histamine H 2 -receptor antagonists (n = 9) were used infrequently, which precluded analysis of a relation between these types of medication and ESBL-E rectal carriage. The distributions of gender, ward type, and medical speciality by which the patient was admitted were comparable for PPI users and non-PPI users. In PPI users, prior hospitalization and antibiotic use were more frequent, and median age was higher (Supplementary Table 1) .
ESBL-E rectal carriage was detected in 31 (5.4%; 95% CI, 3.8%-7.6%) of 570 patients. Escherichia coli (n = 27 [87.1%]) was the predominant species, followed by Klebsiella pneumoniae (n = 3 [9.7%]) and Enterobacter cloacae (n = 1 [3.2%]). No statistically significant differences in the distribution and diversity of ESBL genes were observed between PPI users and non-PPI users (χ 2 = 5.84, P = .322; data shown in Supplementary Table 2 ).
In the univariable analysis, PPI use was found to be statistically significantly associated with ESBL-E rectal carriage (odds ratio [OR], 3.12; 95% CI, 1.41-6.89; Table 1 ). The effects of omeprazole and pantoprazole on ESBL-E rectal carriage were comparable. Hence, overall PPI use was analyzed in the multivariable model. In the multivariable model, PPI use and age were independently associated with ESBL-E rectal carriage ( Table 1) . The prevalence of ESBL-E carriage at admission was higher in PPI users (adjusted OR, 3.89; 95% CI, 1.65-9.19) but lower with increasing age (adjusted OR, 0.976; 95% CI, .955-.998).
DISCUSSION
In the present study, PPI use was independently associated with ESBL-E rectal carriage at hospital admission.
The relation between the use of medication that affects gastric acidity and ESBL-E rectal carriage has been investigated before. A recent Dutch study described a similar effect of PPIs on ESBL-E rectal carriage in primary care patients [3] . This indicates that the effect of PPIs is present in both the community and in patients with more frequent exposure to healthcare. In an Israeli study, the use of histamine H 2 -receptor antagonists, but not PPIs, was associated with ESBL-E rectal carriage [4] . The authors provided no clear explanation for the lack of effect of PPI use. Three other studies on risk factors for ESBL-E rectal carriage did not find an association with gastric-acid suppression therapy in general, but no data were provided on the specific effect of PPIs [6] [7] [8] .
Antibiotic use on the day of culture was not associated with ESBL-E rectal carriage. This is due to the small time window between start of antibiotic use and time of culture in the study population. Unfortunately, no data were available on antibiotic use prior to hospital admission, which has previously been described as a risk factor for ESBL-E rectal carriage [9] . However, a recent Dutch study found that adjustment for prior antibiotic use did not change the effect size of the association between PPI use and ESBL-E carriage [3] .
Strengths of the present study include the high response rate (82.9%), the use of a sensitive culture method, including selective broth enrichment, and the blinded ascertainment of data on medication use and other patient characteristics.
In the present study, data on PPI use pertain to preadmission use. This ensures the use of PPIs shortly before screening for ESBL-E carriage. Other studies have used time windows for PPI use of up to 1 year before culture, which may dilute the observed effect of PPI use on ESBL-E rectal carriage. Data on the duration and dosage of PPI use were not available in this study, which precluded analysis of a dose-effect relationship. Yet, taking into account the frequency and duration of PPI use is expected to increase the observed effect of PPI use on ESBL-E carriage.
No data were available on the presence of comorbidities, which may be a (residual) confounder of the observed association between PPI use and ESBL-E carriage.
Reports on the association between age and ESBL-E carriage have variously described no association, positive associations, and negative associations. These conflicting results may in part be Abbreviations: CI, confidence interval; ESBL-E, extended-spectrum β-lactamase-producing Enterobacteriaceae; IQR, interquartile range; NA, not applicable; OR, odds ratio; PPI, proton pump inhibitor. a Hospital admission in the 6 months prior to the current hospital admission.
due to the positive association between age and PPI use. This may mask the effect of age on ESBL-E rectal carriage when analyses are not adjusted for PPI use, as was shown in the current study. The relevance of PPI use as a risk factor for ESBL-E carriage should be seen in the perspective of PPIs being one of the most frequently prescribed class of drugs in the world [10] . In the Netherlands, between 10% and 15% of the population uses a PPI. Above 65 years of age, the prevalence of PPI use increases to roughly 30% [11] . In the present study, this was even higher (45.4%). This is probably due to the fact that this hospitalderived patient population is older and has more comorbidities and medication use than the general population [12] . The extensive use of PPIs in the general population may facilitate the acquisition of ESBL-E in the community setting.
In conclusion, we found that PPI use is associated with ESBL-E rectal carriage at hospital admission. Prospective studies are warranted to further elucidate the role of PPI use in the acquisition of ESBL-E rectal carriage and may provide insight into the effect of different PPIs or dosage schedules.
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